Cardiac Sarcoidosis

Cardiac sarcoidosis is a genuinely difficult diagnosis to make by imaging alone, and understanding why is more useful than memorizing a single “classic” appearance — because, unlike many of the other conditions in this section, sarcoidosis doesn’t have one.

What Cardiac Sarcoidosis Is

Sarcoidosis is a systemic granulomatous disease of unknown cause that can involve almost any organ. In cardiac sarcoidosis (CS), non-caseating granulomatous tissue infiltrates the heart, producing a clinical spectrum that ranges from entirely asymptomatic involvement to atrioventricular conduction disease, ventricular arrhythmia, and heart failure.

Most patients with cardiac sarcoidosis have extracardiac involvement — the lungs most commonly, though the skin, eyes, liver, and peripheral nerves can all be affected. Isolated cardiac sarcoidosis, without any extracardiac disease, has been well described — which means the absence of extracardiac manifestations should never be used to argue against the diagnosis. Subclinical cardiac involvement is present in up to 20% of patients with systemic sarcoidosis who have no cardiac symptoms at all — a genuinely important reason to think about screening cardiac imaging in a patient with known systemic sarcoidosis, rather than waiting for cardiac symptoms to appear.

No Single Echo Phenotype — This Is the Central Diagnostic Challenge

Unlike most conditions in this section, sarcoidosis doesn’t present with one characteristic echocardiographic appearance. It can resemble several different cardiomyopathy phenotypes in different patients, which is exactly why it appears as a differential consideration across multiple pages in this section rather than fitting neatly into just one:

• Most commonly, it resembles dilated cardiomyopathy — global or regional systolic dysfunction with ventricular dilation, a pattern it shares with cardiac hemochromatosis, another infiltrative cause capable of producing the same dilated phenocopy.
• Occasionally, it presents with asymmetric hypertrophy mimicking hypertrophic cardiomyopathy — a genuine phenocopy worth remembering when working up unexplained LVH, alongside the other red-flag conditions covered on that page.
• Rarely, it can present with restrictive physiology, resembling restrictive cardiomyopathy — and in this presentation, the disease can progress from a restrictive pattern toward systolic impairment in its chronic phase, rather than remaining fixed as a single phenotype over time.

This variability is the single most important thing to internalize about cardiac sarcoidosis: a normal-looking echo pattern for one phenotype doesn’t rule out sarcoidosis presenting as a different one, and the “right” diagnostic approach is recognizing the supporting features below rather than pattern-matching to one expected appearance.

The Most Typical Echocardiographic Feature: Basal Septal Thinning

Basal thinning of the interventricular septum is described as the single most typical echocardiographic feature of cardiac sarcoidosis. The corresponding tissue characterization pattern on cardiac MRI is genuinely specific and worth knowing in detail: subepicardial and mid-wall late gadolinium enhancement at the basal septum, often extending into the inferolateral wall and the right ventricular insertion points. This distribution doesn’t respect a single coronary artery territory — a useful distinguishing feature from ischemic scar, which does.

Regional Wall Motion Abnormalities: A Non-Coronary Pattern

Cardiac sarcoidosis frequently produces regional wall motion abnormalities that follow a non-coronary disease distribution — they don’t correspond to a single vessel’s perfusion territory the way an infarct-related wall motion abnormality does. Finding a regional wall motion abnormality that doesn’t fit a coronary distribution, on either echo or CMR, should itself prompt consideration of myocarditis, ARVC, non-dilated LV cardiomyopathy, or sarcoidosis — not an assumption of atypical or anomalous coronary disease. This is a genuinely useful, general-purpose diagnostic principle worth applying any time a wall motion abnormality doesn’t make clean coronary-anatomic sense.

Other Recognized Findings

• Conduction system abnormalities are common — AV block of varying degrees is a frequent presenting feature, reflecting granulomatous infiltration of the conduction system itself, and can be the first clinical sign of cardiac involvement in an otherwise asymptomatic patient.
• Pericardial effusion is a recognized accompanying finding.
• Ventricular arrhythmia, including sustained ventricular tachycardia, reflects the same patchy granulomatous and scarring process that produces the non-coronary regional wall motion abnormalities above — the scar substrate is arrhythmogenic in the same way post-infarct scar is, just distributed differently.
• LV systolic and diastolic dysfunction can both be present, and the relative severity of each depends on which phenotype (DCM-like, HCM-like, or RCM-like) the individual patient’s disease most resembles.

Why Confirmatory Testing Is Genuinely Difficult — and Why Negative Results Don’t Exclude Disease

Both of the two main confirmatory tools have real, specific limitations worth understanding rather than treating either as a simple yes/no answer.

FDG-PET

18F-FDG-PET identifies myocardial inflammation through a focal, or focal-on-diffuse, pattern of glucose uptake, and is specifically recommended as part of the diagnostic work-up when cardiac sarcoidosis is suspected. A critical limitation: FDG-PET detects active inflammation — a negative scan does not exclude sarcoidosis in its inactive, burnt-out fibrotic form, where inflammation has already resolved into scar. This mirrors a broader pattern seen with other confirmatory tests in late-stage sarcoidosis: even serum markers like ACE and a biopsy specimen can be normal or negative once disease has progressed beyond its active inflammatory phase, genuinely complicating diagnosis specifically in patients presenting late in the disease course.

FDG-PET’s value for distinguishing sarcoidosis from ARVC specifically is limited — both conditions can produce myocardial FDG uptake, since both involve genuine tissue inflammation and remodeling. What actually tips the differential toward sarcoidosis is concomitant FDG uptake in extracardiac tissue, or other clinical features independently suggestive of systemic sarcoidosis — PET uptake in the heart alone doesn’t reliably separate the two conditions.

Endomyocardial Biopsy

Endomyocardial biopsy remains the gold standard for directly identifying cardiac inflammation, and can help differentiate sarcoidosis from myocarditis and from ARVC when non-invasive assessment is inconclusive. Its real limitation is sampling: granulomatous involvement in sarcoidosis is characteristically patchy rather than diffuse, so a biopsy taken from an unaffected region can be falsely negative even with genuine disease present elsewhere in the heart. Because biopsy carries real procedural risk and requires expert pathologic interpretation, it’s reserved for situations where the result would genuinely change management, rather than used routinely. Electroanatomic voltage mapping can help guide biopsy toward abnormal (and therefore more likely to be diagnostic) myocardial regions, particularly when CMR itself is negative or inconclusive.

Sarcoidosis as a Genuine Phenocopy Across Three Differentials

It’s worth drawing together, in one place, just how many different diagnostic pathways sarcoidosis can enter:

• As an HCM phenocopy, alongside amyloidosis, Fabry disease, and the other red-flag conditions covered on the Hypertrophic Cardiomyopathy page, when it produces asymmetric hypertrophy.
• As a DCM mimic, its most common presentation, when it produces dilation with global or regional systolic dysfunction.
• As an ARVC phenocopy specifically — a genuinely important differential, since both conditions characteristically produce right ventricular-predominant disease with ventricular arrhythmia, and distinguishing between them can be a real diagnostic dilemma in practice. This is exactly the setting where the FDG-PET limitation described above matters most, and where endomyocardial biopsy is most often considered specifically to resolve the ambiguity.

How to Diagnose It: A Practical Sequence

1. Don’t expect a single characteristic appearance — approach the study with the DCM-like, HCM-like, and RCM-like presentations all genuinely in mind, rather than screening for one expected pattern.
2. Look specifically at the basal interventricular septum for regional thinning — the single most typical finding — and assess for any regional wall motion abnormality that doesn’t correspond to a coronary distribution.
3. Screen for conduction system involvement on ECG alongside the echo — new or unexplained AV block in a patient without another clear cause is a genuine red flag worth actively correlating with imaging findings.
4. Check for a pericardial effusion, and assess diastolic function and overall chamber size and function across the DCM/HCM/RCM spectrum, since the individual patient’s phenotype determines which findings are most relevant.
5. Take the extracardiac history seriously, but don’t let its absence reassure you — ask specifically about known pulmonary, skin, ocular, hepatic, or neurologic sarcoidosis, while remembering that isolated cardiac disease is a real, described entity.
6. When sarcoidosis is genuinely suspected, recommend cardiac MRI for tissue characterization — looking specifically for the basal septal, inferolateral, and RV insertion point LGE pattern — and consider FDG-PET for active inflammation, understanding that a negative result doesn’t exclude burnt-out disease.
7. Reserve endomyocardial biopsy for cases where non-invasive assessment remains genuinely inconclusive and the result would change management, recognizing its sampling limitation given sarcoidosis’s patchy distribution — and consider electroanatomic mapping-guided biopsy when CMR itself is unrevealing.
8. When RV-predominant disease with ventricular arrhythmia is the presentation, actively hold sarcoidosis and ARVC together as a differential, since distinguishing them specifically often requires the combination of extracardiac FDG-PET findings, biopsy, and the broader clinical picture rather than cardiac imaging alone.

Clinical Importance

Cardiac sarcoidosis rewards a genuinely different diagnostic mindset than most of the conditions covered elsewhere in this section: instead of learning one characteristic pattern to recognize, the real skill is holding multiple possible phenotypes in mind simultaneously, recognizing the basal septal and non-coronary regional findings that cut across all of them, and understanding precisely why a negative PET scan or a normal biopsy doesn’t close the question. Sarcoidosis’s genuine value as a teaching case is exactly this: it’s the condition that most directly tests whether a diagnostic approach depends on pattern-matching or on actually understanding the mechanism and the limitations of the tools being used.